FindTrial
Sign In

High-dose of Intravenous Immunoglobulin Modulates Foxp3+ Treg Cells Expression in Premature Infants

Effect of High-dose of Intravenous Immunoglobulin on Prevention OF Premature Infants

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ORC-16008872
Enrollment
Unknown
Registered
1990-01-01
Start date
2016-07-31
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

premature

Interventions

IVIG infusion:IVIG infusion

Sponsors

Zhongnan Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Infants were consecutively admitted to NICU with a gestational age (GA) between 32 and 36 weeks (GA 32 0/7–36 6/7 weeks)

Exclusion criteria

Exclusion criteria: Premature babies with congenital malformations, autoimmune diseases, and those whose date of birth were missing or uncertain, guardian of the premature infants were unwilling to participate in the study.

Design outcomes

Primary

MeasureTime frame
Foxp3;—

Countries

China

Contacts

Public ContactZHAO DONGCHI

Zhongnan Hospital of Wuhan University

zhao_wh2004@hotmail.com+86 18995540899

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 7, 2026